From Israel to Michigan: AgeTech with Real Economic Potential

Michigan’s aging population is not just a healthcare story. It is an economic development story. The state’s population was estimated at 10,127,884 in 2025, and 19.6% of residents are now 65 or older. At the same time, Michigan already has a meaningful medical technology base, with 1,800+ life sciences and medical device business locations, giving the state a strong foundation for piloting, adopting, and scaling new health technologies.

That is why two Israeli companies, FlowPed and Neteera, are worth attention in Michigan. They are at different stages, but both are working on technologies that respond to the same long-term pressure: how to help older adults stay safer, healthier, and more independent while easing strain on caregivers and care systems. For Michigan, that creates more than a market opportunity. It creates an opening to attract pilots, customers, strategic investors, and long-term company activity tied to one of the state’s clearest demographic needs.

FlowPed is the earlier-stage opportunity. The company’s device uses a remote patient data monitoring solution that provides around-the-clock visibility into a patient’s condition and is intended to support earlier identification of developing dehydration and the onset of urinary infections. The platform also points to a broader vision around urine-based monitoring, daily care insight, and better support for older adults who require consistent incontinence management. That makes it especially relevant for older-adult care, where daily care challenges can quickly become larger clinical events. For Michigan, FlowPed represents the kind of company that could benefit from strategic investors, validation partners, and pilot sites across senior living, rehabilitation, and home-based care.

Neteera is the more market-ready story. The company offers an FDA-cleared contactless patient monitoring platform designed to capture continuous vital sign and activity data without wires or wearables, with a focus on earlier detection and more proactive care. Its Neteera 130H-Plus device is already positioned for healthcare settings where staffing is tight and patient visibility matters, including post-acute and senior-care environments. For Michigan, that makes Neteera a strong fit for customer expansion through health systems, skilled nursing operators, and other care providers looking for more efficient monitoring tools.

Taken together, these companies highlight why Israel’s AgeTech pipeline matters here. FlowPed points to Michigan’s opportunity to engage promising early-stage companies before they are fully built out. Neteera shows what it looks like when a company is further along and ready for commercial growth. Both align with where Michigan is headed: an older population, more demand for aging-in-place solutions, and growing need for technologies that improve care while reducing system burden.

The takeaway is straightforward: AgeTech is not just about better care. It is also about where Michigan can create economic value. Companies like FlowPed and Neteera matter because they sit at the intersection of healthcare need, market demand, and innovation capacity. In a state with aging demographics and a real med-tech base, that is exactly the kind of international innovation worth turning into partnerships, pilots, and growth.